"10.1371_journal.pone.0101764","plos one","2014-07-11T00:00:00Z","Zineb Belcaid; Jillian A Phallen; Jing Zeng; Alfred P See; Dimitrios Mathios; Chelsea Gottschalk; Sarah Nicholas; Meghan Kellett; Jacob Ruzevick; Christopher Jackson; Emilia Albesiano; Nicholas M Durham; Xiaobu Ye; Phuoc T Tran; Betty Tyler; John W Wong; Henry Brem; Drew M Pardoll; Charles G Drake; Michael Lim","Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Oncology and Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Departments of Oncology, Ophthalmology, and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America","Conceived and designed the experiments: ZB JAP JZ APS EA CGD ML. Performed the experiments: ZB JAP JZ APS DM CG SN MK JR CJ. Analyzed the data: ZB JAP JZ APS JR XY ML. Contributed reagents/materials/analysis tools: NMD PTT BT JWW HB DMP. Contributed to the writing of the manuscript: ZB JAP JZ APS DM CJ JR ML.","Michael Lim is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria. Michael Lim is also a speaker for Accuray and receives research funding from Accuray, Bristol-Meyers Squibb, Celldex and Agenus. Charles Drake is a consultant for Bristol-Meyers Squibb, Compugen, Dendreon, and Roche/Genentech and he is an advisor for Aduro and Bristol-Meyers Squibb. He receives research funding from Bristol-Meyers Squibb, Aduro and Medarex and has stock ownership of Compugen. Drew Pardoll is a consultant/advisor for Jounce Therapeutics, Bristol-Meyers Squibb, ImmuneXcite and Aduro and receives research funding from Bristol-Meyers Squibb. Jing Zeng, Michael Lim, Charles Drake and Drew Pardoll hold a patent for the work related to this study. The authors declare that they have a patent relating to material pertinent to this article; this international patent application PCT/US2012/043124 entitled “Use of Adjuvant Focused Radiation Including Stereotactic Radiosurgery for Augmenting Immune Based Therapies Against Neoplasms” was filed 19 June 2012. This application was subsequently filed on the national stage in the United Stage, Europe, Canada, Australia, India and China. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","07","Zineb Belcaid","ZB",20,TRUE,7,10,7,NA,TRUE,TRUE,FALSE,0,NA,FALSE
